Pivot Pharmaceuticals Announces Blue Sky Compliance

BOSTON, MA and VANCOUVER, BC--(Marketwired - March 15, 2016) - Pivot Pharmaceuticals Inc. (OTCQB: PVOTF) (“Pivot” or the “Company”), an emerging biotechnology company engaged in the development of therapeutics to address unmet medical needs in women’s health, is pleased to announced that Blue Sky Monitoring Service has completed its audit and reports that Pivot is now Blue Sky compliant in 47 U.S. states.

Blue Sky laws are U.S. state securities laws established to protect investors from fraud. Broker-dealers are legally not permitted to recommend, solicit or discuss a security with a client unless that security is compliant with the Blue Sky Laws of the state in which the investor resides. These laws are applied in addition to federal securities laws. Blue Sky compliance is mandatory for the 280,000+ U.S. registered investment advisors to advise, discuss, or recommend a company’s stock to their investor clients. By gaining Blue Sky compliance in more jurisdictions, companies are expanding the pool of investors to whom broker-dealers can recommend their stock.

Further, Mergent’s Editorial Board has approved Pivot Pharmaceuticals Inc. for a listing in Mergent Manuals and News Reports™. Pivot’s corporate profile, which includes descriptive text data as well as news and financial statements, will be accessible via Mergent’s online and print products. As part of Mergent’s listing services, the new description will be highlighted separately on www.mergent.com with an active hyperlink back to Pivot’s website.

The Mergent Industrial Manual and News Reports™ is a recognized securities manual in 39 states for purposes of Blue Sky Manual Exemption. First published in 1918, and formerly known as Moody’s™ Manuals and News Reports, the publication was rebranded as Mergent Manuals and News Reports when Mergent, Inc. acquired Moody’s™ Financial Information Services division in 1998. Pivot’s listing will aid the brokerage community in making a market for the company’s stock. However, it is recommended that brokers confirm with their compliance/legal department concerning “Blue Sky” laws in specific states and other regulatory laws that might affect them.

About Mergent, Inc.

Mergent, Inc. is a leading provider of business and financial data on global publicly listed companies. Based in the U.S, Mergent maintains a strong global presence, with offices in New York, Charlotte, San Diego, London, Tokyo, Kuching and Melbourne. Mergent operates one the longest continuously published databases of descriptive and fundamental information as well as pricing and corporate action data on domestic and international companies, together with terms and conditions data on corporate and municipal bonds. Mergent subsidiaries provide services in independent equity research and administration tools for portfolio building and measurement.

About Pivot Pharmaceuticals, Inc.

Pivot is an emerging pharmaceutical company engaged in the development of novel therapies to address unmet medical needs in women’s health including oncology and urology. The Company has a strategic emphasis on innovative drugs that will provide new treatment options for women’s cancers as well as for unmet gynecological and urological problems. Pivot has a portfolio of novel anticancer candidates for the treatment of gynecological and breast cancers and it is also developing novel treatments to address disturbances such as lower urinary tract symptoms (LUTS). The Company has a global drug development platform that combines the strengths of the United States, Canada and India which allows accelerated drug development strategies to provide novel therapeutic options to address unmet medical needs in women’s health.

Cautionary Statement

Except for historical information contained herein, the matters set forth above may be forward-looking statements that involve certain risks and uncertainties that could cause actual results to differ from those in the forward-looking statements. Words such as anticipate, believe, estimate, expect, intend, and similar expressions, as they relate to Pivot Pharmaceuticals or its management, identify forward-looking statements. Such forward-looking statements are based on the current beliefs of management, as well as assumptions made by and information currently available to management. Actual results could differ materially from those contemplated by the forward-looking statements as a result of certain factors, such as the level of business and consumer spending, the amount of sales of Pivot’s products, the competitive environment within the industry, the ability of Pivot to continue to expand its operations, the level of costs incurred in connection with Pivot’s expansion efforts, economic conditions in the industry, and the financial strength of Pivot’s customers and suppliers. Pivot does not undertake any obligation to update such forward-looking statements. Investors are also directed to consider all other risks and uncertainties.